Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 70

1.

Outcomes after bloodstream infection in hospitalized pediatric hematology/oncology and stem cell transplant patients.

Dandoy CE, Kelley T, Gaur AH, Nagarajan R, Demmel K, Alonso PB, Guinipero T, Savelli S, Hakim H, Owings A, Myers K, Aquino V, Oldridge C, Rae ML, Schjodt K, Kilcrease T, Scurlock M, Marshburn AM, Hill M, Langevin M, Lee J, Cooksey R, Mian A, Eckles S, Ferrell J, El-Bietar J, Nelson A, Turpin B, Huang FS, Lawlor J, Esporas M, Lane A, Hord J, Billett AL.

Pediatr Blood Cancer. 2019 Dec;66(12):e27978. doi: 10.1002/pbc.27978. Epub 2019 Sep 5.

PMID:
31486593
2.

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz-Containing Antiretroviral Therapy.

Desta Z, Gammal RS, Gong L, Whirl-Carrillo M, Gaur AH, Sukasem C, Hockings J, Myers A, Swart M, Tyndale RF, Masimirembwa C, Iwuchukwu OF, Chirwa S, Lennox J, Gaedigk A, Klein TE, Haas DW.

Clin Pharmacol Ther. 2019 Oct;106(4):726-733. doi: 10.1002/cpt.1477. Epub 2019 Jul 5.

PMID:
31006110
3.

Model-Based Methods to Translate Adolescent Medicine Trials Network for HIV/AIDS Interventions Findings Into Policy Recommendations: Rationale and Protocol for a Modeling Core (ATN 161).

Neilan AM, Patel K, Agwu AL, Bassett IV, Amico KR, Crespi CM, Gaur AH, Horvath KJ, Powers KA, Rendina HJ, Hightow-Weidman LB, Li X, Naar S, Nachman S, Parsons JT, Simpson KN, Stanton BF, Freedberg KA, Bangs AC, Hudgens MG, Ciaranello AL.

JMIR Res Protoc. 2019 Apr 16;8(4):e9898. doi: 10.2196/resprot.9898.

4.

Pre-vaccination prevalence of anogenital and oral human papillomavirus in young HIV-infected men who have sex with men.

Kahn JA, Belzer M, Chi X, Lee J, Gaur AH, Mayer K, Martinez J, Futterman DC, Stier EA, Paul ME, Chiao EY, Reirden D, Goldstone SE, Ortiz Martinez AP, Cachay ER, Barroso LF, Da Costa M, Wilson CM, Palefsky JM; AIDS Malignancy Consortium and Adolescent Medicine Trials Network for HIV/AIDS Interventions.

Papillomavirus Res. 2019 Jun;7:52-61. doi: 10.1016/j.pvr.2019.01.002. Epub 2019 Jan 15.

5.

Uptake and virological outcomes of single- versus multi-tablet antiretroviral regimens among treatment-naïve youth in the HIV Research Network.

Griffith DC, Farmer C, Gebo KA, Berry SA, Aberg J, Moore RD, Gaur AH, Mathews WC, Beil R, Korthuis PT, Nijhawan AE, Rutstein RM, Agwu AL; HIV Research Network.

HIV Med. 2019 Feb;20(2):169-174. doi: 10.1111/hiv.12695. Epub 2018 Dec 18.

PMID:
30561888
6.

Interest of Youth Living With HIV in Long-Acting Antiretrovirals.

Weld ED, Rana MS, Dallas RH, Camacho-Gonzalez AF, Ryscavage P, Gaur AH, Chakraborty R, Swindells S, Flexner C, Agwu AL.

J Acquir Immune Defic Syndr. 2019 Feb 1;80(2):190-197. doi: 10.1097/QAI.0000000000001896.

PMID:
30418298
7.

Effect of Levofloxacin Prophylaxis on Bacteremia in Children With Acute Leukemia or Undergoing Hematopoietic Stem Cell Transplantation: A Randomized Clinical Trial.

Alexander S, Fisher BT, Gaur AH, Dvorak CC, Villa Luna D, Dang H, Chen L, Green M, Nieder ML, Fisher B, Bailey LC, Wiernikowski J, Sung L; Children’s Oncology Group.

JAMA. 2018 Sep 11;320(10):995-1004. doi: 10.1001/jama.2018.12512. Erratum in: JAMA. 2019 Jul 2;322(1):84.

8.

Safety, efficacy, and pharmacokinetics of single-tablet elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in virologically suppressed, HIV-infected children: a single-arm, open-label trial.

Natukunda E, Gaur AH, Kosalaraksa P, Batra J, Rakhmanina N, Porter D, Shao Y, Zhang H, Pikora C, Rhee MS.

Lancet Child Adolesc Health. 2017 Sep;1(1):27-34. doi: 10.1016/S2352-4642(17)30009-3. Epub 2017 Jun 29.

PMID:
30169223
9.

Treatment and secondary prophylaxis with ethanol lock therapy for central line-associated bloodstream infection in paediatric cancer: a randomised, double-blind, controlled trial.

Wolf J, Connell TG, Allison KJ, Tang L, Richardson J, Branum K, Borello E, Rubnitz JE, Gaur AH, Hakim H, Su Y, Federico SM, Mechinaud F, Hayden RT, Monagle P, Worth LJ, Curtis N, Flynn PM.

Lancet Infect Dis. 2018 Aug;18(8):854-863. doi: 10.1016/S1473-3099(18)30224-X. Epub 2018 Jun 5.

PMID:
29884572
10.

Adverse Effects of Intravenous Vancomycin-Based Prophylaxis during Therapy for Pediatric Acute Myeloid Leukemia.

Sun Y, Huskey RL, Tang L, Inaba H, Gaur AH, Ribeiro R, Rubnitz JE, Wolf J.

Antimicrob Agents Chemother. 2018 Feb 23;62(3). pii: e01838-17. doi: 10.1128/AAC.01838-17. Print 2018 Mar.

11.

A quality improvement initiative to increase Tdap (tetanus, diphtheria, acellular pertussis) vaccination coverage among direct health care providers at a children's hospital.

Jiang C, Whitmore-Sisco L, Gaur AH, Adderson EE; Tdap Working Group.

Vaccine. 2018 Jan 4;36(2):214-219. doi: 10.1016/j.vaccine.2017.11.071. Epub 2017 Dec 6.

PMID:
29217370
12.

Levofloxacin Prophylaxis During Induction Therapy for Pediatric Acute Lymphoblastic Leukemia.

Wolf J, Tang L, Flynn PM, Pui CH, Gaur AH, Sun Y, Inaba H, Stewart T, Hayden RT, Hakim H, Jeha S.

Clin Infect Dis. 2017 Nov 13;65(11):1790-1798. doi: 10.1093/cid/cix644.

13.

Guideline for the Management of Fever and Neutropenia in Children With Cancer and Hematopoietic Stem-Cell Transplantation Recipients: 2017 Update.

Lehrnbecher T, Robinson P, Fisher B, Alexander S, Ammann RA, Beauchemin M, Carlesse F, Groll AH, Haeusler GM, Santolaya M, Steinbach WJ, Castagnola E, Davis BL, Dupuis LL, Gaur AH, Tissing WJE, Zaoutis T, Phillips R, Sung L.

J Clin Oncol. 2017 Jun 20;35(18):2082-2094. doi: 10.1200/JCO.2016.71.7017. Epub 2017 May 1. Review.

PMID:
28459614
14.

A Prospective, Holistic, Multicenter Approach to Tracking and Understanding Bloodstream Infections in Pediatric Hematology-Oncology Patients.

Gaur AH, Bundy DG, Werner EJ, Hord JD, Miller MR, Tang L, Lawlor JP, Billett AL; Children’s Hospital Association Childhood Cancer & Blood Disorders Network (CCBDN).

Infect Control Hosp Epidemiol. 2017 Jun;38(6):690-696. doi: 10.1017/ice.2017.57. Epub 2017 Apr 12.

PMID:
28399945
15.

Use of Placebo Pills Before Treatment Initiation in Youth with HIV: Are They Ready?

Ingerski LM, Wilkins ML, Rach AM, Patel N, Gaur AH.

J Int Assoc Provid AIDS Care. 2017 Jul/Aug;16(4):412-417. doi: 10.1177/2325957417702483. Epub 2017 Apr 10.

PMID:
28393664
16.

Body Image and Risk Behaviors in Youth with HIV.

Dallas RH, Loew MM, Wilkins ML, Sun Y, Tang L, Porter JS, Gaur AH.

AIDS Patient Care STDS. 2017 Apr;31(4):176-181. doi: 10.1089/apc.2016.0259. Epub 2017 Mar 23.

PMID:
28332857
17.

The impact of the UGT1A1*60 allele on bilirubin serum concentrations.

Pasternak AL, Crews KR, Caudle KE, Smith C, Pei D, Cheng C, Broeckel U, Gaur AH, Hankins J, Relling MV, Haidar CE.

Pharmacogenomics. 2017 Jan;18(1):5-16. doi: 10.2217/pgs-2016-0135. Epub 2016 Dec 14.

PMID:
27967321
18.

Safety, efficacy, and pharmacokinetics of a single-tablet regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in treatment-naive, HIV-infected adolescents: a single-arm, open-label trial.

Gaur AH, Kizito H, Prasitsueubsai W, Rakhmanina N, Rassool M, Chakraborty R, Batra J, Kosalaraksa P, Luesomboon W, Porter D, Shao Y, Myers M, Ting L, SenGupta D, Quirk E, Rhee MS.

Lancet HIV. 2016 Dec;3(12):e561-e568. doi: 10.1016/S2352-3018(16)30121-7. Epub 2016 Oct 17.

PMID:
27765666
19.

Central Line Associated Blood Stream Infections in Pediatric Hematology/Oncology Patients With Different Types of Central Lines.

Hord JD, Lawlor J, Werner E, Billett AL, Bundy DG, Winkle C, Gaur AH; Children's Hospital Association Childhood Cancer and Blood Disorders Network.

Pediatr Blood Cancer. 2016 Sep;63(9):1603-7. doi: 10.1002/pbc.26053. Epub 2016 May 16.

PMID:
27198806
20.

The Impact of Youth-Friendly Structures of Care on Retention Among HIV-Infected Youth.

Lee L, Yehia BR, Gaur AH, Rutstein R, Gebo K, Keruly JC, Moore RD, Nijhawan AE, Agwu AL; HIV Research Network.

AIDS Patient Care STDS. 2016 Apr;30(4):170-7. doi: 10.1089/apc.2015.0263. Epub 2016 Mar 16.

21.

Characterizing Body Image in Youth with HIV.

Wilkins ML, Dallas RH, Porter JS, Tang L, Sun Y, Magdovitz-Frankfurt P, Gaur AH.

AIDS Behav. 2016 Aug;20(8):1585-90. doi: 10.1007/s10461-015-1271-z.

PMID:
26721247
22.

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir Prescribing.

Gammal RS, Court MH, Haidar CE, Iwuchukwu OF, Gaur AH, Alvarellos M, Guillemette C, Lennox JL, Whirl-Carrillo M, Brummel SS, Ratain MJ, Klein TE, Schackman BR, Caudle KE, Haas DW; Clinical Pharmacogenetics Implementation Consortium.

Clin Pharmacol Ther. 2016 Apr;99(4):363-9. doi: 10.1002/cpt.269. Epub 2015 Nov 9. Review.

23.

The Impact of Vaccine Concerns on Racial/Ethnic Disparities in Influenza Vaccine Uptake Among Health Care Workers.

Ojha RP, Stallings-Smith S, Flynn PM, Adderson EE, Offutt-Powell TN, Gaur AH.

Am J Public Health. 2015 Sep;105(9):e35-41. doi: 10.2105/AJPH.2015.302736. Epub 2015 Jul 16.

24.

The HIV Care Continuum: Changes over Time in Retention in Care and Viral Suppression.

Yehia BR, Stephens-Shields AJ, Fleishman JA, Berry SA, Agwu AL, Metlay JP, Moore RD, Christopher Mathews W, Nijhawan A, Rutstein R, Gaur AH, Gebo KA; HIV Research Network.

PLoS One. 2015 Jun 18;10(6):e0129376. doi: 10.1371/journal.pone.0129376. eCollection 2015.

25.

Aging and loss to follow-up among youth living with human immunodeficiency virus in the HIV Research Network.

Agwu AL, Lee L, Fleishman JA, Voss C, Yehia BR, Althoff KN, Rutstein R, Mathews WC, Nijhawan A, Moore RD, Gaur AH, Gebo KA.

J Adolesc Health. 2015 Mar;56(3):345-51. doi: 10.1016/j.jadohealth.2014.11.009.

26.

Safety and immunogenicity of an intranasal Sendai virus-based human parainfluenza virus type 1 vaccine in 3- to 6-year-old children.

Adderson E, Branum K, Sealy RE, Jones BG, Surman SL, Penkert R, Freiden P, Slobod KS, Gaur AH, Hayden RT, Allison K, Howlett N, Utech J, Allay J, Knight J, Sleep S, Meagher MM, Russell CJ, Portner A, Hurwitz JL.

Clin Vaccine Immunol. 2015 Mar;22(3):298-303. doi: 10.1128/CVI.00618-14. Epub 2014 Dec 31.

27.

Effective treatment of cerebral mucormycosis associated with brain surgery.

Chamdine O, Gaur AH, Broniscer A.

Pediatr Infect Dis J. 2015 May;34(5):542-3. doi: 10.1097/INF.0000000000000626.

28.

Preventing CLABSIs among pediatric hematology/oncology inpatients: national collaborative results.

Bundy DG, Gaur AH, Billett AL, He B, Colantuoni EA, Miller MR; Children’s Hospital Association Hematology/Oncology CLABSI Collaborative.

Pediatrics. 2014 Dec;134(6):e1678-85. doi: 10.1542/peds.2014-0582. Epub 2014 Nov 17.

29.

A piece of my mind. Pause, listen, share.

Cantrell KA, Sutton S, Gaur AH.

JAMA. 2014 Jul 23-30;312(4):345-6. doi: 10.1001/jama.2014.6201. No abstract available.

PMID:
25038350
30.

Feasibility, efficacy, and adverse effects of outpatient antibacterial prophylaxis in children with acute myeloid leukemia.

Inaba H, Gaur AH, Cao X, Flynn PM, Pounds SB, Avutu V, Marszal LN, Howard SC, Pui CH, Ribeiro RC, Hayden RT, Rubnitz JE.

Cancer. 2014 Jul 1;120(13):1985-92. doi: 10.1002/cncr.28688. Epub 2014 Mar 26.

31.

PG4KDS: a model for the clinical implementation of pre-emptive pharmacogenetics.

Hoffman JM, Haidar CE, Wilkinson MR, Crews KR, Baker DK, Kornegay NM, Yang W, Pui CH, Reiss UM, Gaur AH, Howard SC, Evans WE, Broeckel U, Relling MV.

Am J Med Genet C Semin Med Genet. 2014 Mar;166C(1):45-55. doi: 10.1002/ajmg.c.31391. Epub 2014 Mar 11.

32.

Trends in hospitalizations among children and young adults with perinatally acquired HIV.

Berry SA, Gebo KA, Rutstein RM, Althoff KN, Korthuis PT, Gaur AH, Spector SA, Warford R, Yehia BR, Agwu AL; HIV Research Network.

Pediatr Infect Dis J. 2014 May;33(5):488-94. doi: 10.1097/INF.0000000000000126.

33.

The use of cell phone support for non-adherent HIV-infected youth and young adults: an initial randomized and controlled intervention trial.

Belzer ME, Naar-King S, Olson J, Sarr M, Thornton S, Kahana SY, Gaur AH, Clark LF; Adolescent Medicine Trials Network for HIV/AIDS Interventions.

AIDS Behav. 2014 Apr;18(4):686-96. doi: 10.1007/s10461-013-0661-3.

34.

Evaluating application of the National Healthcare Safety Network central line-associated bloodstream infection surveillance definition: a survey of pediatric intensive care and hematology/oncology units.

Gaur AH, Miller MR, Gao C, Rosenberg C, Morrell GC, Coffin SE, Huskins WC.

Infect Control Hosp Epidemiol. 2013 Jul;34(7):663-70. doi: 10.1086/671005. Epub 2013 May 21.

PMID:
23739069
35.

Conformity of pediatric/adolescent HIV clinics to the patient-centered medical home care model.

Yehia BR, Agwu AL, Schranz A, Korthuis PT, Gaur AH, Rutstein R, Sharp V, Spector SA, Berry SA, Gebo KA.

AIDS Patient Care STDS. 2013 May;27(5):272-9. doi: 10.1089/apc.2013.0007.

36.

Prechewing and prewarming food for HIV-exposed children: a prospective cohort experience from Latin America.

Gaur AH, Cohen RA, Read JS, Freimanis Hance L, Dominguez K, Alarcon JO, Menezes J, Peixoto MF, Mussi-Pinhata MM, Coelho DF, Mitchell C, Siberry GK.

AIDS Patient Care STDS. 2013 Mar;27(3):142-5. doi: 10.1089/apc.2012.0459. No abstract available.

37.

Surveillance of hospital-acquired central line-associated bloodstream infections in pediatric hematology-oncology patients: lessons learned, challenges ahead.

Gaur AH, Bundy DG, Gao C, Werner EJ, Billett AL, Hord JD, Siegel JD, Dickens D, Winkle C, Miller MR; Children's Hospital Association Hematology-Oncology Quality Transformation Collaborative Project.

Infect Control Hosp Epidemiol. 2013 Mar;34(3):316-20. doi: 10.1086/669513. Epub 2013 Jan 22.

PMID:
23388370
38.

Prospective detection of respiratory pathogens in symptomatic children with cancer.

Srinivasan A, Gu Z, Smith T, Morgenstern M, Sunkara A, Kang G, Srivastava DK, Gaur AH, Leung W, Hayden RT.

Pediatr Infect Dis J. 2013 Mar;32(3):e99-e104. doi: 10.1097/INF.0b013e31827bd619.

39.

Delayed entry into and failure to remain in HIV care among HIV-infected adolescents.

Minniear TD, Gaur AH, Thridandapani A, Sinnock C, Tolley EA, Flynn PM.

AIDS Res Hum Retroviruses. 2013 Jan;29(1):99-104. doi: 10.1089/AID.2012.0267. Epub 2012 Nov 7.

PMID:
23033848
40.

Optimizing frequency of CD4 assays in the era of highly active antiretroviral therapy.

Gaur AH, Flynn PM, Bitar W, Liang H.

AIDS Res Hum Retroviruses. 2013 Mar;29(3):418-22. doi: 10.1089/AID.2012.0175. Epub 2012 Oct 31.

41.

Predictors of highly active antiretroviral therapy utilization for behaviorally HIV-1-infected youth: impact of adult versus pediatric clinical care site.

Agwu AL, Siberry GK, Ellen J, Fleishman JA, Rutstein R, Gaur AH, Korthuis PT, Warford R, Spector SA, Gebo KA.

J Adolesc Health. 2012 May;50(5):471-7. doi: 10.1016/j.jadohealth.2011.09.001. Epub 2011 Nov 4.

42.

Premastication as a route of pediatric HIV transmission: case-control and cross-sectional investigations.

Ivy W 3rd, Dominguez KL, Rakhmanina NY, Iuliano AD, Danner SP, Borkowf CB, Denson AP, Gaur AH, Mitchell CD, Henderson SL, Paul ME, Barton T, Herbert-Grant M, Hader SL, Pérez García E, Malachowski JL, Nesheim SR.

J Acquir Immune Defic Syndr. 2012 Feb 1;59(2):207-12. doi: 10.1097/QAI.0b013e31823b4554.

PMID:
22027873
43.

Motivating factors for high rates of influenza vaccination among healthcare workers.

Hakim H, Gaur AH, McCullers JA.

Vaccine. 2011 Aug 11;29(35):5963-9. doi: 10.1016/j.vaccine.2011.06.041. Epub 2011 Jun 23.

PMID:
21699950
44.

Disparities in antiretroviral treatment: a comparison of behaviorally HIV-infected youth and adults in the HIV Research Network.

Agwu AL, Fleishman JA, Korthuis PT, Siberry GK, Ellen JM, Gaur AH, Rutstein R, Gebo KA; HIV Research Network.

J Acquir Immune Defic Syndr. 2011 Sep 1;58(1):100-7. doi: 10.1097/QAI.0b013e31822327df.

45.

Psychological factors, beliefs about medication, and adherence of youth with human immunodeficiency virus in a multisite directly observed therapy pilot study.

Garvie PA, Flynn PM, Belzer M, Britto P, Hu C, Graham B, Neely M, McSherry GD, Spector SA, Gaur AH; Pediatric AIDS Clinical Trials Group (PACTG) P1036B Team.

J Adolesc Health. 2011 Jun;48(6):637-40. doi: 10.1016/j.jadohealth.2010.09.014. Epub 2010 Dec 18.

46.

Knowledge and practice of prechewing/prewarming food by HIV-infected women.

Gaur AH, Freimanis-Hance L, Dominguez K, Mitchell C, Menezes J, Mussi-Pinhata MM, Peixoto MF, Alarcon J, Coelho DF, Read JS.

Pediatrics. 2011 May;127(5):e1206-11. doi: 10.1542/peds.2010-1902. Epub 2011 Apr 11.

47.

Severe H1N1-associated acute respiratory failure in immunocompromised children.

Elbahlawan L, Gaur AH, Furman W, Jeha S, Woods T, Norris A, Morrison RR.

Pediatr Blood Cancer. 2011 Oct;57(4):625-8. doi: 10.1002/pbc.22973. Epub 2011 Feb 4.

PMID:
21298770
48.

Incidence of and risk factors for community acquired pneumonia in US HIV-infected children, 2000-2005.

Steenhoff AP, Josephs JS, Rutstein RM, Gebo KA, Siberry GK, Gaur AH, Warford R, Korthuis PT, Spector SA, Shah SS.

AIDS. 2011 Mar 13;25(5):717-20. doi: 10.1097/QAD.0b013e3283440583.

49.

Directly observed therapy (DOT) for nonadherent HIV-infected youth: lessons learned, challenges ahead.

Gaur AH, Belzer M, Britto P, Garvie PA, Hu C, Graham B, Neely M, McSherry G, Spector SA, Flynn PM; Pediatric AIDS Clinical Trials Group P1036B Team.

AIDS Res Hum Retroviruses. 2010 Sep;26(9):947-53. doi: 10.1089/aid.2010.0008.

50.

Antiretroviral therapy in HIV-infected infants and children.

Marón G, Gaur AH, Flynn PM.

Pediatr Infect Dis J. 2010 Apr;29(4):360-3. doi: 10.1097/INF.0b013e3181d616d8. No abstract available.

PMID:
20351530

Supplemental Content

Support Center